About Avience Biomedicals IPO
Avience Biomedicals IPO Details
Avience Biomedicals IPO is 14.53 lakh equity shares worth up to ₹30 crore, entirely a fresh issue of 0.15 crore shares, with a face value of ₹10 per share. The company filed its DRHP with SEBI on June 12, 2026.
The price band of this issue is set at ₹196 to ₹208 per share and the lot size for an application is 600 shares. The minimum amount required by an individual investor (retail investor) is ₹2,49,600 (1,200 shares). The IPO will be open for subscription from June 18 to 22, 2026, on the NSE SME platform with a tentative listing date fixed as June 25, 2026. The book-running lead manager of the issue is FinTellectual Corporate Advisors Pvt. Ltd., while the registrar of the offer is Skyline Financial Services Pvt. Ltd.
Avience Biomedicals IPO Date & Timeline
The Avience Biomedicals IPO is officially set to open for subscription on Jun 18, 2026 and will close on Jun 22, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on June 12, 2026 and has now finalized its schedule following SEBI approval. Once the subscription window allotment is expected on Jun 23, 2026. Following this, the company will initiate refunds and credit shares to successful investors' demat accounts on Jun 24, 2026. Finally, Avience Biomedicals Ltd.'s shares are tentatively scheduled to list on the stock exchanges on Jun 25, 2026.
Avience Biomedicals IPO Timeline
| IPO Open Date | Thu, Jun 18, 2026 |
| IPO Close Date | Mon, Jun 22, 2026 |
| Tentative Allotment | Tue, Jun 23, 2026 |
| Initiation of Refunds | Wed, Jun 24, 2026 |
| Credit of Shares to Demat | Wed, Jun 24, 2026 |
| Tentative Listing Date | Thu, Jun 25, 2026 |
| Cut-off time for UPI mandate confirmation | - |
Avience Biomedicals IPO Details
| Detail | Description |
|---|---|
| IPO Date | 18 to 22 Jun, 2026 |
| Listing Date | 25 Jun, 2026 |
| Face Value | ₹ 10 per share |
| Issue Price Band | ₹ 196 to ₹ 208 |
| Lot Size | 600 |
| Sale Type | Fresh Capital |
| Total Issue Size | 14,53,800 shares (agg. up to ₹ 30 Cr) |
| Reserved for Market Maker | 82,200 shares (agg. up to ₹ 2 Cr) Asnani Stock Broker Pvt.Ltd. |
| Fresh Issue(Ex Market Maker) | 13,71,600 shares (agg. up to ₹ 29 Cr) |
| Offer for Sale | - |
| Net Offered to Public | 13,71,600 shares (agg. up to ₹ 29 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 40,31,256 shares |
| Share Holding Post Issue | 54,85,056 shares |
Avience Biomedicals IPO GMP (Grey Market Premium)
“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.
The Avience Biomedicals IPO GMP is currently trading at ₹85, reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹293, which is 40.87% above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.
Avience Biomedicals GMP TREND (DAILY UPDATES)
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| 20 Jun 2026 | ₹208 | ₹85 | 20 Jun, 202612:01 PM |
| 19 Jun 2026 | ₹208 | ₹85 | 19 Jun, 202609:58 AM |
| 18 Jun 2026 | ₹208 | ₹75 | 18 Jun, 202612:54 PM |
| 17 Jun 2026 | ₹208 | ₹75 | 17 Jun, 202612:23 PM |
| 16 Jun 2026 | ₹208 | ₹63 | 17 Jun, 202609:53 AM |
| 15 Jun, 2026 | ₹208 | ₹70 | 15 Jun, 202610:18 AM |
Company Background
Avience Biomedicals Ltd. was incorporated on December 23, 2019, as a private limited company in Delhi; then, on September 03, 2024, the company converted into a public limited company to proceed with its public listing procedures. The initial focus of the company was on affordable diagnostic solutions to address critical healthcare needs during periods of heightened medical emergencies. The company has steadily expanded its presence across India while also establishing selected touchpoints in overseas markets.
The establishment of Avience Biomedicals Ltd. was at the time of the Covid-19 pandemic; it is a medical consumable company dedicated to the manufacturing of in vitro diagnostic (IVD) products and medical devices in Noida. The company has achieved ISO certificate, which shows its commitment to perfection and quality strictness. With this stock exchange listing, the company will mainly focus on its financial statements and
Operations & Product Range
Avience Biomedicals Ltd. focuses on providing diagnostic solutions across different segments of the healthcare sector. While it initially gained recognition for essential diagnostic products such as Viral Transport Media (VTM), the company has since expanded its portfolio to include In-Vitro Diagnostic (IVD) rapid test kits for HIV, Malaria, Dengue and HBs AG, along with serology products, biochemistry analyzers and biochemistry reagents. These products are supplied to healthcare institutions, pathology networks, commercial laboratories and multi-speciality clinical settings.
Facilities & Capacity
Avience Biomedicals Ltd. currently carries out its manufacturing and assembly operations from a leasehold facility in Noida, Uttar Pradesh, which serves as its main production and assembly centre. To support future growth, the company has been allotted 2,100 square metres of industrial land in the YEIDA Medical Device Park at Uttar Pradesh. The planned investment will be used to develop a modern multi-floored cleanroom facility, with the objective of improving production efficiency and significantly expanding manufacturing capacity across its existing product range.
Brands & Market Presence
Avience Biomedicals Ltd. is expanding its presence across both domestic and international markets, supported by certifications including ISO and a ZED MSME Gold rating. In India, its strongest presence is in Delhi, Uttar Pradesh and Haryana, which have historically generated the largest share of domestic sales. The company also serves institutional buyers in international markets such as Dubai, Ethiopia, Ghana, Somalia, Zambia and Nepal.
Revenue Streams & Business Model
Avience Biomedicals Ltd. generates revenue primarily through trading operations, manufacturing activities and supporting clinical services. For January 31, 2026, trading operations remained the largest contributor, generating ₹19.67 crore and accounting for 68.44% of standalone sales, while the manufacturing segment contributed ₹8.82 crore or 30.70%. The company’s revenue is largely driven by domestic business, with exports providing additional foreign exchange earnings, which totalled ₹5.24 crore during the whole FY25.
Management & Shareholding
The promoter group of Avience Biomedicals Ltd. are Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary. Before the public issue, the promoters and promoter group collectively held 87.89% of the company’s paid-up equity share capital. Following the fresh issue, their shareholding is expected to dilute to 64.59%, increasing the public shareholding while allowing the promoter group to retain majority voting control of the company.
Board & Key Management
Avience Biomedicals Ltd. is led by an experienced management team. Mr. Dharam Deo Choudhary serves as Chairman and also oversees the company’s day-to-day operations as Managing Director, supported by Whole-Time Directors Mr. Ram Nagina Choudhary and Mrs. Deepa Choudhary. The board also includes Independent Directors Mr. Pankaj Sharma and Mr. Om Prakash Pal, who provide independent oversight and support good corporate governance, helping guide the company’s growth and operations.
Avience Biomedicals IPO Financial Information
Latest Revenue
28.75
₹ Crore
Profit After Tax
4.18
₹ Crore
Net Worth
24.7
₹ Crore
Total Borrowing
17.17
₹ Crore
| Period Ended | Assets | Total Income | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 31 Jan 2026 | 51.96 | 28.75 | 4.18 | 24.7 | 20.67 | 17.17 | |||
| 31 Mar 2025 | 56.52 | 28.89 | 7.29 | 22.85 | 18.82 | 22.15 | |||
| 31 Mar 2024 | 34.65 | 10.63 | 2.15 | 6.23 | 2.94 | 15.13 | |||
| Amount in ₹ Crore | |||||||||
Avience Biomedicals Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 18.49 % |
| ROCE | 15.16 % |
| Debt/Equity | 0.69 |
| RoNW | 18.49 % |
| PAT Margin | - |
| EBITDA Margin | 24.7 % |
| Price to Book Value | 3.39 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 12.74 | 9.15 |
| P/E (x) | 16.33 | 22.74 |
Avience Biomedicals IPO Objectives
The company is mainly aims to utilise its Avience Biomedicals IPO proceeds for strategic purposes:
- • Funding the setting up of a new manufacturing facility in Uttar Pradesh.
- • Funding the working capital requirements.
- • General corporate purposes.
Avience Biomedicals IPO Review
Avience Biomedicals Ltd. operates in the medical diagnostics and laboratory equipment sector through a hybrid business model that combines third-party product trading with localised manufacturing. The company
Financially, the company has shown steady growth and profit on financial statements; as for FY25, the revenue from operations was reported at ₹45.23 crore and PAT was at ₹7.23 crore with an EBITDA of ₹11.41 crore. Notably, the top 10 customers contributed around ₹16.35 crore, which is 56.82% of the revenue from operations.
However, the company operates in a highly regulated industry where changes in compliance requirements or delays in obtaining cross-border product licenses could affect operations. Investors must be aware of the company’s potential risk too before investing, including a 50% dependency on repeat customers or failure in niche sectors. Overall, the IPO shows a chance for potential investors to invest in growing sectors, but the problem is it comes with certain risks. Investors need to review the RHP carefully before making decisions.
Conclusion
Avience Biomedicals IPO is an opportunity for investors to invest in a growing company that is gradually transitioning from a trading-focused business model to a more integrated manufacturing-driven operation. It aims to benefit from the growing domestic diagnostics industry through its planned infrastructure development in Uttar Pradesh. With this listing, the company mainly focus on the expansion of its facility as the manufacturing facility unit is setting up in Uttar pradesh.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Diversified Product Portfolio: Offers an expansive matrix ranging from basic rapid testing kits to advanced biochemistry reagents and clinical analyzers.
Established Distribution Footprint: Maintained active commercial linkages with an expanding network of 78 specialized dealers and medical distributors as of early 2026.
Strategic Regulatory Infrastructure: Operates under verified ISO certifications and institutional approvals aligned with national central drug control expectations.
Dual-Engine Business Framework: Effectively reduces operational volatility by combining swift trading turnarounds with structural product manufacturing.
Download regulatory filings
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 1200 | 249600 |
| Individual investors (Retail) (Max) | 2 | 1200 | 249600 |
| S-HNI (Min) | 3 | 1800 | 374400 |
| S-HNI (Max) | 8 | 4800 | 998400 |
| B-HNI (Min) | 9 | 5400 | 1123200 |